Small Cap Feast

17th January 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:

No joiners today.

Arricano Real Estate has left AIM. 

What’s Cooking In The IPO Kitchen?

Celsius Resources intends to join AIM. Currently ASX listed, Celsius is a natural resources exploration and development company principally seeking to explore and develop potential world-class copper-gold assets in the Philippines and a cobalt asset in Namibia. Amount planning to raise and anticipated market cap TBC. Expected late January 2023.

Conviction Life Sciences, a newly established closed-ended investment company managed by Plain English Finance Limited, is seeking to list on Premium Segment of the Main Market of the London Stock Exchange, to invest in a conviction portfolio of life sciences and medical technology businesses, primarily in the UK, Europe and Australasia. The Company will invest in both Publicly Traded and Private companies - c. 70% and c. 20% of the total portfolio value respectively. The Company will target an annualised Total NAV Return of 20% over the long-term. Targeting to raise c.£100m. Delayed to 3rd February 2023.

Breakfast Buffet

Corero Network Security 8.5p £42.5m (CNS.L)
A leading provider of real-time, high-performance, automatic Distributed Denial of Service (DDoS) cyber defence solutions, provides a trading update for the year ended 31 December 2022. Order intake, which reflects revenues recognised over the lifetime of each of the contracts, was $23.9m for the year ended 31 December 2022 with growth of 13% over the prior year (2021: $21.2m). Annualised Recurring Revenues (ARR) increased to $14.4m as at 1 January 2023, an increase of 13% over the prior year (ARR at 1 January 2022: $12.8m), driven by strong demand for Corero's subscription-based and DDoS Protection as-a-service (DDPaaS) products, which underpins higher levels of earnings predictability for the Company going forward. Notwithstanding the growth in order intake and ARR, revenue for the year ending 31 December 2022 is expected to be approximately $20.1m (2021: $20.9m), and therefore below market guidance. Adjusted EBITDA for the year ending 31 December 2022 is now expected to be in the range of $1.4 - $1.8m.

hVIVO 15.4p £103.3m (HVO.L)
The growing specialist contract research organisation and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its consultancy services division, Venn Life Sciences, has signed a contract with a major global pharmaceutical client worth EUR3.2m over 2 years. The contract commences in January 2023, with the Venn team in Breda providing dedicated complex clinical pharmacokinetics (PK) consultancy and programming services to this global pharmaceutical client on a number of drug development programmes across multiple therapeutic areas, to study the absorption, distribution and excretion of drugs within the body.

Kibo Energy* 0.14p £4.3m (KIBO.L)
The renewable-energy-focused development company announces its decision to potentially produce synthetic oil from non-recyclable plastic waste at its 7 MW plastic-to-syngas power plant, which sits within the 65%-owned Sustineri Energy. This can potentially enhance the project’s profitability, generate revenue much earlier than initially anticipated and make the project more attractive to a wider spectrum of interested funders. As a result of this decision, the project will be divided into two phases. Phase 1 will involve the installation of a materials preparation system, a pyrolysis chamber and condensers that will produce synthetic oil product(s). In Phase 2, the pyrolysis chamber temperature will be elevated to produce syngas that will be fed to newly installed gas engines for electricity generation.

N4 Pharma 2.15p £5.0m (N4P.L)
The specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA. The Company has now completed two in vivo studies demonstrating that Nuvec® loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.

Naked Wines 133p £98.4m (WINE.L)
The wine retailer provides a trading update for the quarter ended 26 December 2022. As a result of a solid Q3 trading performance with flat reported revenue vs prior year, improved year-on-year repeat customer contribution margins and tightly controlled SG&A expenses, FY23 adjusted EBIT outlook increased to £13-17m, from previous guidance of £9-13m. However, the consumer and marketing environment remains challenging and opportunities to invest in new customer recruitment at attractive payback levels continue to be limited. The Company expect to spend £20-24m on new customer investment in FY23, around 40% below FY22 levels. This is below the run rate necessary to maintain current scale and therefore a modest decline in revenue in FY24 is likely.

Pressure Technologies 39.5p £15.3m (PRES.L)
The specialist engineering group, announces the appointment of Steve Hammell as Chief Financial Officer. Mr Hammell will join the Company and Board in the second quarter of this calendar year. Steve is currently CFO of Sheffield Forgemasters International Ltd, a world leader in the manufacture of ultra-heavy forgings and castings that serves a wide range of industry sectors, including UK and international defence markets.

Ramsdens Holdings 216.5p £68.5m (RFX.L)
The diversified financial services provider and retailer, announces its annual results for the year ended 30 September 2022. Revenue increased from £40.7m to £66.1m. Revenue in Ramsden’s four core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second-hand and new jewellery increased throughout the period. Profit before tax increased to £8.3m (FY21: £0.6m). Profit for the Group has been driven primarily by the strong recovery in foreign currency gross profit to £12.6m (FY21: 3.3m) as international travel returned to a reasonable level. Q1 FY23 trading update (October to December 2022): Jewellery retail gross profit increased by over 15%; Q1 volumes of foreign currency exchange remained at approximately 70% of pre pandemic levels; The pawnbroking loan book has grown further from the year-end balance of £8.6m to £9.1m and the purchase of precious metal volumes and its other services have continued to perform in line with expectations.

Renold 26.2p £59.1m (RNO.L)
A international supplier of industrial chains and related power transmission products, announces that Renold Couplings, part of the Company's Torque Transmission division, has been awarded a contract worth £8.7m. The award, to be delivered over the 7 years, is for the supply of flexible couplings for the Royal Australian Navy's Hunter class frigates. The flexible couplings, which are an important component of a ship's propulsion system, are part of Renold's Hi-Tec range of couplings, which are supplied worldwide for large marine and industrial projects. Production of the couplings is expected to commence in early 2023, and will be machined on a new machining centre which was installed in Renold's Cardiff facility in 2022, specifically for naval programmes. The first manufacturing programme is scheduled to complete in 2030.

Revolution Bars 5.45p £12.5m (RBG.L)
A leading operator of 90 premium pubs and bars, trading mainly under the Revolution, Revolucion de Cuba and Peach Pub brands, announces a trading update for the 26 weeks ended 31 December 2022. In the 5 weeks to 31 December 2022 like for like (LFL) sales for the group were up 17.3% compared to the same period in 2021 despite the period being affected by industrial action. When compared to the same period in 2019, the last Christmas period not affected by Covid 19, group sales are down 9%. Overall in H1, the 26 weeks ended 31 December, compared to the same period in 2019, LFL sales in the Group were down 9.4%. The Board has reassessed its expectations of the Group's FY23 that the IAS 17 EBITDA outturn for the year, including rental costs, is likely to be lower than previously guided and is estimated to be at the bottom end of the range of market expectations, of £6.7-10.5m.

Quiz 16.275p £20.2m (QUIZ.L)
The omni-channel fashion brand, announces an update on trading for the period between 1 December 2022 to 31 December 2022 and its current cash position. Total Group sales in the Period increased by 11%, year on year to £9.8m. This performance reflected strong customer demand for QUIZ's trademark dressy occasionwear in the first Christmas period in 3 years not impacted by COVID-19 related social restrictions. Group revenues in the 9 months to 31 December 2022 totalled £75.2m, representing a 23% increase on the £61m generated in the equivalent period in the previous year. As at 16 January 2023, the Group had total liquidity headroom of £12.7m, being a cash balance of £9.2m and £3.5m of undrawn bank facilities. The Board remains confident it will deliver profits for the full year to 31 March 2023 at least in line with its expectations and is well positioned to achieve further profitable revenue growth in the longer term.

17 January 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram